Nagawa(00001.HK) announced that the company owns about 60.15% of its subsidiaries and Huang China Pharmaceutical Technology, and has granted 18,000 share options to several of its eligible employees to subscribe to Hehuang China Pharmaceutical Technology's common stock with a face value of US$1 per share. The exercise price of the granted shares is £42.2 per share of Hehuang China Pharmaceutical Technology Co., Ltd. and is valid from May 21, 2019 to May 20, 2029. (ta/w) (Quotation delayed at least 15 minutes. (The short selling information is as of 2019-05-22 16:25.)
长和(00001.HK)：和黄中国医药科技向若干合资格雇员授出认股权
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.